ArticleJournal of thrombosis and haemostasis : JTH2016
Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
Article in Journal of thrombosis and haemostasis : JTH, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 5 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Accuracy of the COMPASS-CAT thrombosis risk assessment scale in predicting venous thromboembolism in cancer patients: a meta-analysis.Journal of thrombosis and thrombolysis · 2024Pooled it
- Lung cancer mortality and associated predictors: systematic review using 32 scientific research findings.Frontiers in oncology · 2023Pooled it
- Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.Blood advances · 2020Pooled it
- The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.Haematologica · 2019Pooled it
- Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Trial
- Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study.Haematologica · 2017Trial
- Development and Validation of a Risk Score for Prediction of Venous Thromboembolism in Patients With Lung Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisTrial
- Pulmonary Embolism in Patients with Lung Cancer: Incidence and Performance of Prognostic Markers.Cancers · 2026Article
- Construction and verification of a nomogram to predict the probability of venous thromboembolism in lung cancer patients.Frontiers in molecular biosciences · 2026Article
- Association of risk factors for venous thromboembolism and overall survival in lung cancer.Blood vessels, thrombosis & hemostasis · 2025Article
- The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer.Medicina (Kaunas, Lithuania) · 2025Article
- Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis.Frontiers in oncology · 2025Article
- Preoperative thrombocytopenia as a predictor of cancer-associated thromboembolism in gastric cancer patients undergoing gastrectomy.Frontiers in oncology · 2025Article
- Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors.BMC pulmonary medicine · 2024Article
- DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.Nature medicine · 2024Article
- The Alfalfa-inpatient-CAT assessment model: a thrombotic risk assessment model for inpatient cancer patients.BMC cancer · 2024Article
- Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival.Research and practice in thrombosis and haemostasis · 2024Article
- Review
- The Application of Existing Risk Assessment Models (RAMS) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin Lymphoma.Journal of clinical medicine · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
unlabelledEssentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all-cause mortality. Our findings stress the need for a lung cancer-specific VTE risk assessment model. SUMMARY: Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non-small cell lung cancer and 40% had metastatic disease at inception. The median follow-up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4-20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5-15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4-2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.